Essential Properties Realty Trust, Inc. (NYSE:EPRT) Receives $25.93 Consensus PT from Analysts

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its target price lowered by Stifel Nicolaus from $5.30 to $5.00 in a research report sent to investors on Thursday, The Fly reports. Several other analysts also recently weighed in on the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating […]

Related Keywords

Rudolf Jaenisch ,Philip Beachy ,Stifel Nicolaus ,Michael Rudnicki ,Leonard Zon ,Alexander Rives ,Scott Wolchko ,David Scadden ,Blackrock Inc ,Nasdaq ,Pricet Rowe Associates Inc ,Vanguard Group Inc ,Wells Fargo Company ,Fate Therapeutics Inc ,Redmile Group Llc ,Fate Therapeutics ,Get Rating ,Director Redmile Group ,Street Corp ,Capital World Investors ,World Investors ,Sheng Ding ,Fate Therapeutics Daily ,Nasdaq Fate ,Fate ,Medical ,Lower Price Target ,